Sales of Spectrum's drug Fusilev for patients with metastatic colorectal cancer remain strong heading into the remainder of 2014, said the company's CEO Rajesh Shrotriya. Total revenue was $46.9 million in Spectrum's second quarter, up 41% from the prior year. Fusilev accounted for $26.6 million of Spectrum's sales in the second quarter, or 56% of total revenue. Outside Fusilev, Shrotriya expects to make a Phase 3 Go/No-Go decision by the end of the year for SPI-2012, a long-acting GCSF drug which he believes could be a 'potential blockbuster'. Finally, Shrotriya said he is seeing a strong sales trajectory for Spectrum's drug Beleodaq for the treatment of patients suffering from peripheral T-cell lymphoma.

If you liked this article you might like

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug